Fig. 9. Hypothesis for the role of H+-V-ATPase in LR patterning; the
pepperoni model. We propose the following model to account for the extant
data on early LR patterning events in Xenopus. In control embryos,
asymmetric H+-V-ATPase activity is necessary for the establishment
of both a pH and a Vmem gradient. The Vmem gradient
provides the motive force to move a small charged morphogen (herein called
`inhibitor of leftness' or IOL) unidirectionally through gap junctions.
Because there are no gap junctions connecting the two cells across the ventral
midline (Levin and Mercola,
1998), the concentration of IOL will increase in the right ventral
region. This increase in concentration is required for IOL activity, i.e.
there is a threshold concentration for IOL to work. We further propose that
IOL activity also requires a particular pH to function. Again, as a result of
asymmetric H+-V-ATPase activity, only the right ventral region
reaches the required pH. Under these conditions, IOL can be active only in the
right ventral region, where it triggers side-appropriate downstream events.
Heterotaxia I: any treatment that interferes with the Vmem gradient
will prevent IOL from reaching threshold concentration. We believe this
explains the heterotaxia that results from treatments with
H+-V-ATPase inhibitors, expression of the dominant-negative subunit
E, expression of ectopic H+-pumps that change the normal pattern of
H+-flux and treatment with palytoxin, which destroys
Vmem entirely. The concentration requirement also explains the
heterotaxia caused by blocking GJC (Levin
and Mercola, 1998), although the mechanism is distinct from that
caused by changing Vmem. Heterotaxia II: This model also predicts
that any treatment pushing the pH in the right ventral region beyond an
acceptable range will cause heterotaxia. We believe this is why heterotaxia
results when embryos are treated with H+-V-ATPase inhibitors,
dominant-negative subunit E, the low pH of the medium and the electroneutral
change in pH caused by treatment with tributyltin or by expression of
NHE3.